Comparison between serum nephrin and microalbuminuria as biomarkers for sickle cell nephropathy

Обложка

Цитировать

Полный текст

Аннотация

Sickle cell anemia is the most common monogenic blood disorder. The most common genotype is homozygous hemoglobin SS. Damage to red blood cells occurs due to changes in shape and function of the hemoglobin molecule inside it. This results in hemolytic anemia and the blockade of small blood vessels, which lead to vaso-occlusion and end organ failure. Sickle cell disease significantly alters renal structure and function and causes diverse renal diseases. To evaluate the validity of serum nephrin as a biomarker of sickle nephropathy and compare its sensitivity versus urinary microalbuminuria in the early detection of sickle cell nephropathy. This case control study was conducted on sixty patients suffering from sickle cell disease, 10 of them were diagnosed as sickle nephropathy, in addition to sixty apparently healthy children as a control group. Laboratory tests were hemoglobin electrophoresis, urinary microalbumin, serum ferritin, urea and creatinine. The glomerular filtration rate was estimated and serum nephrin was measured using enzymelinked immunosorbent assay. Among children with sickle cell anemia, 16.6% (10 patients) had sickle nephropathy diagnosed with elevated kidney function and low glomerular filtration rate. Liver and kidney function were significantly higher in cases with nephropathy than cases without nephropathy, while glomerular filtration rate was significantly lower in cases with nephropathy than cases without nephropathy. Serum nephrin was significantly higher in patients with nephropathy than patients without nephropathy versus non-significant difference regarding microalbuminuria level. The cutoff point for nephrin to diagnose sickle cell nephropathy was > 13 ng/mL versus 29.5 mg/dL for urinary microalbumin. Serum nephrin could be a valuable biomarker in early diagnosis of nephropathy in patients with sickle cell anemia.

Об авторах

Mahmoud Ahmed El-Hawy

Menoufia University

Email: Mahmodelhawy18@yahoo.com

Menoufia

Египет

Samar Elsayed Tawfik El-Mistekawy

Menoufia University

Email: dr_naboelkhair@yahoo.com

Menoufia

Египет

Noran Talaat Aboelkhair

Menoufia University

Email: zeinab_sabri@yahoo.com

Menoufia

Египет

Zeinab Sabri Abouzouna

Menoufia University

Автор, ответственный за переписку.
Email: zeinab_sabri@yahoo.com
ORCID iD: 0000-0002-1270-8175

Zeinab Sabri Abouzouna, MD, Lecturer in Pediatrics, Department of Pediatrics

Shebin El Kom, 32511 Menoufia

Египет

Список литературы

  1. Neumayr L.D., Hoppe C.C., Brown C. Sickle cell disease: current treatment and emerging therapies. Am J Manag Care 2019; 25 (18): 335–43.
  2. Ansari J., Moufarrej Y.E., Pawlinski R., Gavins F.N. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. Exp Rev Hematol 2018; 11 (1): 45–55.
  3. El-Beshlawy A., Youssry I. Prevention of hemoglobinopathies in Egypt. Hemoglobin 2009; 33 (suppl 1): S14–20.
  4. Olaniran K.O., Eneanya N.D., Nigwekar S.U., Vela-Parada X.F., Achebe M.M., et al. Sickle cell nephropathy in the pediatric population. Blood Purif 2019; 47 (1–3): 205–13.
  5. Tal R. The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod 2012; 87 (6): 134.
  6. Maier-Redelsperger M., Noguchi C.T., de Montalembert M., Rodgers G.P., Schechter A.N., Gourbil A., et al., Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood 1994; 84 (9): 3182–8.
  7. Quinn C.T., Rogers Z.R., McCavit T.L., Buchanan G.R. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115 (17): 3447–52.
  8. Bartolucci P., Habibi A., Stehlé T., di Liberto G., Rakotoson M.G., Gellen-Dautremer J., et al. Six months of hydroxyurea reduces albuminuria in patients with sickle cell disease. J Am Soc Nephrol 2016; 27 (6): 1847–53.
  9. Brett Heimlich J., Speed J.S., O'Connor P.M., Pollock J.S., Townes T.M., Meiler S.E., et al. Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species. Br J Pharmacol 2016; 173 (2): 386–95.
  10. Thompson J., Reid M., Hambleton I., Serjeant G.R. Albuminuria and renal function in homozygous sickle cell disease: observation from cohort study. Arch Intern Med 2007; 167: 701–8.
  11. McKie K.T., Hanevold C.D., Hernandez C., Waller J.L., Ortiz L., McKie K.M. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J Pediatric Hematol Oncol 2007; 29 (3): 140–4.
  12. Heimlich J., Chipoka G., Elsherif L., David E., Ellis G., Kamthunzi P., et al. Nephrin as a Biomarker of Sickle Cell Glomerulopathy in Malawi. Pediatr Blood Cancer 2018; 65 (6): e26993.
  13. Sundd P., Gladwin M.T., Novelli E.M. Pathophysiology of sickle cell disease. Annu Rev Pathol 2019; 14: 263–92.
  14. Youssry I., Makar S., Fawzy R., Wilson M., AbdAllah G., Fathy E., et al. Novel marker for the detection of sickle cell nephropathy: soluble FMS-like tyrosine kinase-1 (sFLT1). Pediatr Nephrol 2015; 30 (12): 2163–8.
  15. Moraleda C., Aguilar R., Quintó L., Nhampossa T., Renom M., Nhabomba A., et al. Anaemia in hospitalised preschool children from a rural area in Mozambique: a case control study in search for etiological agents. BMC Pediatric 2017; 17 (1): 63.
  16. Zaini R.G. Sickle-cell anemia and consanguinity among the Saudi Arabian population. Arch Med 2016; 8 (3): 3–15.
  17. Hamad AL-Mijallib S., Adilc H., Nasird A., Abdelaald D.E., Haroone B.E., Abd Elfataha R. The Role of Consanguinity in the frequency of Sickle cell anaemia in North Kordofan state. 2012; 12 (1): 1–13.
  18. Nandanwar R.A., Kamd N.Y. Sickle cell disease affects physical growth. Int J Pharm Bio Sci 2013; 4: 784–9.
  19. Rodrigues L., Costa F.F., Saad S.T. High levels of neopterin and interleukin-3 in sickle cell disease patients. J Clin Lab Anal 2006; 20 (3): 75–9.
  20. Akodu S.O., Diaku-Akinwumi I.N., Njokanma O.F. Obesity – Does It Occur in Nigerian Children with Sickle Cell Anemia. Pediatr Hematol Oncol 2012; 29 (4): 358–64
  21. Isaza-López M.C., Rojas-Rosas L.F., Echavarría-Ospina L., Serna-Higuita L.M. Caracterización de las complicaciones renales en pacientes con anemia de células falciformes. Rev Chil Pediatr 2020; 91 (1): 51–7.
  22. Geard A., Pule G.D., Chetcha Chemegni B., Ngo Bitoungui V.J., Kengne A.P., Chimusa E.R., Wonkam A. Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. Br J Haematol 2017; 178 (4): 629–39.
  23. Nding’uri W.W. Sickle cell nephropathy among children and adolescents with sickle cell disease at Bungoma County Referral Hospital (Doctoral dissertation, Moi University). 2021; 21 (75): 1486–93.
  24. Benneh-Akwasi Kuma A., Owusu-Ansah A.T., Ampomah M.A., Sey F., Olayemi E., Nouraie M., et al. Prevalence of relative systemic hypertension in adults with sickle cell disease in Ghana. PLoS One 2018; 13 (1): e0190347.
  25. Kadhim D.A., Al-Dujaili A.N. Estimation of nephrin level in sickle cell anemia patients associated with nephropathy. InAIP Conference Proceedings. AIP Publishing LLC 2020; 2290 (1): 20040.
  26. Sofue T., Kiyomoto H., Kobori H., Urushihara M., Nishijima Y., Kaifu K., et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 2012; 25 (5): 604–11.
  27. Petrica L., Ursoniu S., Gadalean F., Vlad A., Gluhovschi G., Dumitrascu S., et al. Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus. Diabetol Metab Syndr 2017; 9: 31.
  28. Becton L.J., Kalpatthi R.V., Rackoff E., Disco D., Orak J.K., Jackson S.M., et al. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatr Nephrol 2010; 25 (8): 1505–11.
  29. Alvarez O., Lopez-Mitnik G., Zilleruelo G. Short-term follow-up of patients with sickle cell disease and albuminuria. Pediatr Blood Cancer 2008; 50 (6): 1236–9.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© El-Hawy M., El-Mistekawy S., Aboelkhair N., Abouzouna Z., 2023

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.